Reynders McVeigh Capital Management LLC Sells 30,453 Shares of Becton, Dickinson and Company $BDX

Reynders McVeigh Capital Management LLC lessened its holdings in Becton, Dickinson and Company (NYSE:BDX) by 77.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 8,891 shares of the medical instruments supplier’s stock after selling 30,453 shares during the period. Reynders McVeigh Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $1,345,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Smith Chas P & Associates PA Cpas grew its stake in Becton, Dickinson and Company by 54.1% in the second quarter. Smith Chas P & Associates PA Cpas now owns 3,132 shares of the medical instruments supplier’s stock valued at $474,000 after purchasing an additional 1,100 shares during the last quarter. Miramontes Capital LLC bought a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at about $420,000. Core Capital Management & Research inc. bought a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at about $4,863,000. Tidal Investments LLC grew its position in shares of Becton, Dickinson and Company by 22.4% in the 2nd quarter. Tidal Investments LLC now owns 146,408 shares of the medical instruments supplier’s stock worth $22,156,000 after buying an additional 26,790 shares during the last quarter. Finally, National Pension Service raised its stake in shares of Becton, Dickinson and Company by 7.0% during the 2nd quarter. National Pension Service now owns 596,647 shares of the medical instruments supplier’s stock worth $90,291,000 after acquiring an additional 38,982 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Piper Sandler raised their target price on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Royal Bank Of Canada increased their price objective on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a report on Thursday, August 13th. TD Cowen boosted their target price on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. Jefferies Financial Group reaffirmed a “buy” rating and set a $210.00 target price on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Finally, Wells Fargo & Company boosted their price target on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Becton, Dickinson and Company has an average rating of “Hold” and a consensus price target of $187.67.

Becton, Dickinson and Company Stock Performance

Shares of NYSE:BDX traded up $2.87 on Tuesday, hitting $185.78. 2,087,411 shares of the company were exchanged, compared to its average volume of 2,558,622. The firm has a market capitalization of $51.19 billion, a P/E ratio of 55.96, a price-to-earnings-growth ratio of 12.53 and a beta of 0.21. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $193.07. The stock’s 50 day moving average price is $173.06 and its 200 day moving average price is $160.49.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The company had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same quarter last year, the business posted $3.68 EPS. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Sell-side analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be paid a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 126.51%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Garrison sold 1,100 shares of the company’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the sale, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. This trade represents a 7.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 8,005 shares of company stock worth $1,423,580. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells products used by healthcare providers, researchers and pharmaceutical companies. Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, the company is headquartered in Franklin Lakes, New Jersey.

BD’s products support medication delivery, infection prevention, diagnostics and surgical care. Its portfolio includes needles, syringes, injection devices, infusion products, medication-management systems, specimen-collection products, laboratory instruments and diagnostic technologies.